Gold-Peptide Cluster Molecules for Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current osteoporosis treatments, including gold nanoparticles, face challenges in stability and cytotoxicity, with existing modifications not effectively inhibiting osteoclast formation and bone resorption, necessitating a more stable and non-toxic therapeutic agent.
Innovation Solution
The development of stable metallic gold-peptide cluster molecules, stabilized with gold-binding peptide molecules, which are administered intraperitoneally or orally to mitigate bone loss by inhibiting the RANKL signaling pathway and reducing osteoclast differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gold nanoparticles are used for osteoporosis treatment, then osteoclast formation can be inhibited, but stability and cytotoxicity issues arise
Solution Approach 1:
The patent combines gold nanoparticles with peptide molecules to form a composite structure. The peptide coating stabilizes the gold nanoparticle surface, preventing aggregation and improving solubility, while the gold core maintains the therapeutic function of inhibiting osteoclast formation through RANKL pathway interference.
Solution Approach 2:
The patent optimizes the size parameter of gold nanoparticles (controlling diameter within specific ranges) and adjusts the peptide-to-gold ratio to achieve the desired balance between stability and therapeutic effectiveness. By controlling particle size and surface chemistry parameters, the patent resolves the contradiction between nanoparticle stability and cytotoxicity.
2Stability of the object's composition
If existing gold nanoparticle modifications are applied, then stability improves, but cytotoxicity is not effectively reduced
Solution Approach 1:
The peptide molecules serve as an intermediary layer between the gold nanoparticle core and the biological environment. This peptide coating mediates the interaction by providing biocompatibility and reducing direct contact between the metal surface and cells, thereby lowering cytotoxicity while maintaining stability.
3Stability of the object's composition
If modifications are made to improve stability, then therapeutic agent stability increases, but effectiveness in inhibiting osteoclast formation decreases
Solution Approach 1:
The patent applies local quality by functionalizing only the surface of the gold nanoparticles with peptides, while maintaining the bulk gold core properties. This localized modification provides stability through the peptide coating without interfering with the gold core's ability to inhibit osteoclast formation, thus resolving the contradiction between stability and effectiveness.
Data Source
AI summary
A therapeutic method for mitigating bone loss. This method includes preparing and administering to animals intraperitoneally or orally a therapeutic agent containing metallic gold cluster molecules as an active ingredient.